- Home
- GLPG vs KN Comparison
GLPG vs KN Comparison
Compare GLPG & KN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLPG
- KN
- Stock Information
- Founded
- GLPG 1999
- KN 1946
- Country
- GLPG Belgium
- KN United States
- Employees
- GLPG N/A
- KN N/A
- Industry
- GLPG Biotechnology: Pharmaceutical Preparations
- KN Consumer Electronics/Appliances
- Sector
- GLPG Health Care
- KN Consumer Staples
- Exchange
- GLPG Nasdaq
- KN Nasdaq
- Market Cap
- GLPG 2.1B
- KN 2.0B
- IPO Year
- GLPG 2005
- KN N/A
- Fundamental
- Price
- GLPG $29.89
- KN $23.04
- Analyst Decision
- GLPG Hold
- KN Buy
- Analyst Count
- GLPG 4
- KN 3
- Target Price
- GLPG $30.00
- KN $22.33
- AVG Volume (30 Days)
- GLPG 209.6K
- KN 759.0K
- Earning Date
- GLPG 11-05-2025
- KN 10-23-2025
- Dividend Yield
- GLPG N/A
- KN N/A
- EPS Growth
- GLPG N/A
- KN N/A
- EPS
- GLPG N/A
- KN 0.48
- Revenue
- GLPG $323,674,692.00
- KN $573,500,000.00
- Revenue This Year
- GLPG $1.77
- KN $8.20
- Revenue Next Year
- GLPG $0.44
- KN $5.13
- P/E Ratio
- GLPG N/A
- KN $48.28
- Revenue Growth
- GLPG 5.43
- KN 4.24
- 52 Week Low
- GLPG $22.36
- KN $12.19
- 52 Week High
- GLPG $37.78
- KN $24.54
- Technical
- Relative Strength Index (RSI)
- GLPG 34.46
- KN 47.06
- Support Level
- GLPG $30.92
- KN $22.62
- Resistance Level
- GLPG $31.85
- KN $23.88
- Average True Range (ATR)
- GLPG 0.81
- KN 0.67
- MACD
- GLPG -0.27
- KN -0.13
- Stochastic Oscillator
- GLPG 1.70
- KN 22.52
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About KN Knowles Corporation
Knowles Corp is engaged in the manufacturing of micro-acoustic microphones and balanced armature speakers, audio solutions, high-performance capacitors, and radio frequency filtering products. It operates in two segments; the Precision Devices segment specializes in the design and delivery of high-performance capacitor products and RF solutions; and Medtech & Specialty Audio segment designs and manufactures microphones and balanced armature speakers used in applications. The majority of its revenue comes from the Precision Devices. Geographically, it operates in United States, Asia, Other Americas, Europe and Others, out of which United States generates maximum revenue.